新一代PRMT5抑制剂PEP08

Search documents
牵手百诚医药推进AI新药研发合作,晶泰控股今年以来股价翻番
Zheng Quan Shi Bao Wang· 2025-09-25 14:49
晶泰控股称,这是与智擎生技合作取得的重要阶段性成果,再一次验证了公司平台高效赋能药物创新的 交付能力。晶泰控股将继续依托其AI+机器人药物研发平台,助力更多合作伙伴加速发现具有市场潜力 和差异化竞争力的创新药物,为更多患者带来优质高效的治疗选择。 据介绍,百诚医药拥有经验丰富的创新药精锐研发团队,已逐步构建起从靶点发现到全球商业化的全链 条创新能力,同时具有较强的药品研发、生产转化以及申报注册的能力与经验。 晶泰控股今年以来动作频频,近日公司宣布,由其助力智擎生技制药(PharmaEngine,Inc.)发现的 新一代PRMT5抑制剂PEP08已达成重要临床研发里程碑。PEP08近日分别获得澳大利亚人类临床研究伦 理委员会(HREC)、澳洲药物管理局(TGA)及中国台湾地区"卫生福利部食品药物管理 署"(TFDA)的临床试验批准,标志着该药物即将启动I期临床试验。基于此进展,晶泰控股确认获得 该项目的里程碑付款。 近期AI医疗概念股表现火爆,作为这一领域的代表性标的,晶泰控股(02228.HK)连续4个交易日股价 出现异动,9月25日其股价大涨5.63%至12.57港元/股,创下近一年新高。从年内涨幅来看,晶 ...
晶泰科技涨超5% 助力智擎生技新药获临床实验审批 公司AI制药业务商业化稳步推进
Zhi Tong Cai Jing· 2025-09-18 03:15
Core Viewpoint - JingTai Technology (02228) has seen a stock increase of over 5% following the announcement of a significant clinical development milestone for the new generation PRMT5 inhibitor PEP08, which has received clinical trial approvals in Australia and Taiwan [1] Group 1: Clinical Development - JingTai Technology announced that the PRMT5 inhibitor PEP08 has achieved important clinical research milestones, receiving approvals from the Human Research Ethics Committee (HREC) in Australia, the Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA) for clinical trials [1] - The initiation of Phase I clinical trials for PEP08 is imminent, marking a significant step in its development [1] Group 2: Financial Performance - JingTai Technology confirmed receipt of milestone payments related to the PEP08 project, contributing positively to its financial performance [1] - According to招商证券, the company's AI pharmaceutical business is steadily advancing, with a projected year-on-year growth rate of 615% in drug discovery business by the first half of 2025 [1] Group 3: Strategic Partnerships - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - JingTai Technology has completed a pipeline cooperation agreement with DoveTree, with a total order scale of 5.99 billion USD, and has received an initial payment of 51 million USD as per the agreement [1] Group 4: Technological Advancements - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physics computing, multimodal AI, and automation platforms [1]